Systematic evaluation of butylphthalide soft capsule in the treatment of cognitive dysfunction in Parkinsons disease

Objective To systematically evaluate the efficacy of butylphthalide soft capsule in the treatment of cognitive impairment in Parkinson's disease. Methods Randomized controlled trials of butylphthalide soft capsules in the treatment of cognitive impairment in Parkinson's disease were retrieved from domestic and foreign databases. Revman 5.1 was used for meta-analysis. Results A total of 9 articles and 755 subjects were included. Compared with the control group, butylphthalide soft capsules could significantly reduce UPDRS score[MD=-11.16,95%CI(-14.07 to-8.25), P<0.001], and increase MoCA score[MD=3.22, 95% CI(2.39-4.05), P<0.001], MMSE score[MD=3.05, 95% CI(2.24-3.87), P<0.001], and ADL score[MD=13.05, 95% CI(11.53-14.57, P<0.001]. It could significantly reduce CRP level[MD=-2.69, 95% CI(-2.69 to-2.27), P<0.001] and PARK7 level[MD=-10.88, 95% CI(-12.35 to-9.40), P<0.001], and significantly increase NT-3 level[MD=8.48, 95% CI(7.35-9.61), P<0.001]. Conclusion Butylphthalide soft capsule can significantly improve the cognitive impairment of Parkinson's disease. However, there are some limitations in this study, which still need to be verified by a better clinical randomized controlled study.